Sverige - svenska - Läkemedelsverket (Medical Products Agency)

zoetis animal health aps - mycoplasma hyopneumoniae, stam p-5722-3, inaktiverad - injektionsvätska, emulsion - polysorbat 80 0,34 mg adjuvans; borax hjälpämne; tiomersal hjälpämne; mycoplasma hyopneumoniae, stam p-5722-3, inaktiverad 1 rp aktiv substans; poloxamer 2,04 mg adjuvans; skvalan 3,24 mg adjuvans; karbomer 4 mg adjuvans - svin

Europeiska unionen - svenska - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - grisar - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ceva phylaxia co. ltd - mycoplasma hyopneumoniae, stam 2940, inaktiverad - injektionsvätska, emulsion - mycoplasma hyopneumoniae, stam 2940, inaktiverad 328 elisa e aktiv substans; lipopolysackarid (lps), escherichia coli, stam j5 0 - 38000 e adjuvans; tiomersal hjälpämne; paraffin, lättflytande 187 mikrol adjuvans - mykoplasmavaccin - svin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

intervet international b.v. - mycoplasma hyopneumoniae, stam 11, inaktiverad - injektionsvätska, emulsion - paraffin, lättflytande 34,6 mg adjuvans; all-rac-alfa-tokoferylacetat 2,5 mg adjuvans; mycoplasma hyopneumoniae, stam 11, inaktiverad 6,5 log2 ab-enheter aktiv substans - svin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fort dodge animal health holland - mycoplasma hyopneumoniae, stam p-5722-3, inaktiverad - injektionsvätska, suspension - mycoplasma hyopneumoniae, stam p-5722-3, inaktiverad 9,3 log10 mhdce aktiv substans; tiomersal hjälpämne; amarant hjälpämne - mykoplasmavaccin - svin

Europeiska unionen - svenska - EMA (European Medicines Agency)

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inaktiverade virala och inaktiverade bakteriella vacciner - grisar - för aktiv immunisering av grisar från 3 veckors ålder mot svinscirkovirus typ 2 (pcv2) för att minska viral belastning i blod och lymfoida vävnader och fekal avverkning orsakad av infektion med pcv2. för aktiv immunisering av grisar över 3 veckors ålder mot mycoplasma hyopneumoniae för att minska lungskador orsakad av infektion med m. hyopneumoniae.

Europeiska unionen - svenska - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologiska medel för suidae - grisar (för gödning) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

intervet international b.v. - mycoplasma hyopneumoniae, stam 11, inaktiverad - injektionsvätska, suspension - mycoplasma hyopneumoniae, stam 11, inaktiverad 7 log2 ab-enheter aktiv substans; all-rac-alfa-tokoferylacetat 150 mg adjuvans - mykoplasmavaccin - svin

Europeiska unionen - svenska - EMA (European Medicines Agency)

pharmsure veterinary products europe ltd - mycoplasma synoviae-stam ms-h - immunologicals för aves, live bakteriella vacciner - kyckling - för aktiv immunisering av framtida könsuppfödarehönor, framtida lageruppfödarehönor och framtida lagerhönor för att minska sårskador och minska antalet ägg med onormal skalbildning orsakad av mycoplasma synoviae.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

merial s.a.s. - mycoplasma hyopneumoniae, inaktiverat antigen - injektionsvätska, suspension - aluminiumoxid, hydratiserad 4,2 mg adjuvans; tiomersal hjälpämne; mycoplasma hyopneumoniae, inaktiverat antigen 3 elisa e aktiv substans - mykoplasmavaccin - svin